eyes—but in big pharma the story goes like this: the low-hanging fruit of medical research has all been harvested, and the industry is rapidly running out of novel molecular entities. They registered fifty a year in the 1990s, but now it’s down to twenty a year, and a lot of those are just copies. They are in trouble.
